AU2008319366B2 - Benzomorpholine derivatives and methods of use - Google Patents

Benzomorpholine derivatives and methods of use Download PDF

Info

Publication number
AU2008319366B2
AU2008319366B2 AU2008319366A AU2008319366A AU2008319366B2 AU 2008319366 B2 AU2008319366 B2 AU 2008319366B2 AU 2008319366 A AU2008319366 A AU 2008319366A AU 2008319366 A AU2008319366 A AU 2008319366A AU 2008319366 B2 AU2008319366 B2 AU 2008319366B2
Authority
AU
Australia
Prior art keywords
compound
usa
compounds
agents
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008319366A
Other languages
English (en)
Other versions
AU2008319366A1 (en
Inventor
Mina Dilmeghani Seran
Jean-Christophe Harmange
Jay Larrow
Matthew W. Martin
Joseph F. Payack
Raju Subramanian
Yohannes Teffera
Ryan White
Roger Zanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2008319366A1 publication Critical patent/AU2008319366A1/en
Application granted granted Critical
Publication of AU2008319366B2 publication Critical patent/AU2008319366B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008319366A 2007-10-29 2008-10-28 Benzomorpholine derivatives and methods of use Ceased AU2008319366B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94807P 2007-10-29 2007-10-29
US61/000,948 2007-10-29
PCT/US2008/012224 WO2009058267A2 (en) 2007-10-29 2008-10-28 Benzomorpholine derivatives and methods of use

Publications (2)

Publication Number Publication Date
AU2008319366A1 AU2008319366A1 (en) 2009-05-07
AU2008319366B2 true AU2008319366B2 (en) 2012-03-01

Family

ID=40394086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008319366A Ceased AU2008319366B2 (en) 2007-10-29 2008-10-28 Benzomorpholine derivatives and methods of use

Country Status (8)

Country Link
US (1) US7795254B2 (OSRAM)
EP (1) EP2220078B1 (OSRAM)
JP (1) JP5343082B2 (OSRAM)
AU (1) AU2008319366B2 (OSRAM)
CA (1) CA2703257C (OSRAM)
ES (1) ES2417009T3 (OSRAM)
MX (1) MX2010004620A (OSRAM)
WO (1) WO2009058267A2 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684182A5 (de) 1991-10-15 1994-07-29 Escher Wyss Ag Rotationsdruckmaschine.
CN102892762B (zh) * 2010-05-19 2016-04-20 桑多斯股份公司 制备泊沙康唑中间体
BR112012029225B1 (pt) 2010-05-19 2020-10-27 Sandoz Ag processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
MX2012013331A (es) 2010-05-19 2013-02-01 Sandoz Ag Purificacion de posaconazol y de intermediarios de posaconazol.
CA2838051C (en) 2011-06-16 2019-09-24 Sandoz Ag Process for the preparation of a chiral compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
WO1996023774A1 (en) 1995-01-31 1996-08-08 Zenyaku Kogyo Kabushiki Kaisha Thioquinoline derivatives
GB9505702D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd Fungicidal compounds
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
EP0802914B1 (en) 1995-11-14 2001-06-06 PHARMACIA & UPJOHN S.p.A. Aryl- and heteroaryl- purine and pyridopyrimidine derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU3534699A (en) 1998-04-23 1999-11-08 Takeda Chemical Industries Ltd. Naphthalene derivatives, their production and use
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
EE200100528A (et) 1999-04-12 2003-02-17 Aventis Pharma Limited Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
WO2003040108A1 (en) 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
MXPA04007459A (es) 2002-02-01 2005-09-08 Astrazeneca Ab Compuestos de quinazolina.
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
KR100942073B1 (ko) 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 ＴＧＦ β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물
WO2004078114A2 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use

Also Published As

Publication number Publication date
WO2009058267A3 (en) 2010-06-10
EP2220078B1 (en) 2013-05-22
US20090149454A1 (en) 2009-06-11
CA2703257C (en) 2013-02-19
JP2011502147A (ja) 2011-01-20
AU2008319366A1 (en) 2009-05-07
US7795254B2 (en) 2010-09-14
JP5343082B2 (ja) 2013-11-13
WO2009058267A2 (en) 2009-05-07
CA2703257A1 (en) 2009-05-07
ES2417009T3 (es) 2013-08-05
MX2010004620A (es) 2010-07-28
EP2220078A2 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
US7687522B2 (en) Substituted pyridines and pyrimidines and their use in treatment of cancer
EP1881976B1 (en) Substituted amide derivatives as protein kinase inhibitors
EP3170824B1 (en) A 6-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-1,6-naphthyridin-5(6h)-one derivative as c-met inhibitor
EP2118069B1 (en) Bis-aryl amide derivatives useful for the treatment of cancer
EP2125780B1 (en) Substituted heterocycles and methods of use
AU2009248839B2 (en) Heterocycles as protein kinase inhibitors
AU2008319366B2 (en) Benzomorpholine derivatives and methods of use
HK1116161B (en) Substituted amide derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PAYACK, JOSEPH F.; SUBRAMANIAN, RAJU; MARTIN, MATTHEW W.; TEFFERA, YOHANNES; LARROW, JAY; ZANON, ROGER; DILMEGHANI SERAN, MINA; HARMANGE, JEAN-CHRISTOPHE AND WHITE, RYAN.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTORS TO READ WHITE, RYAN; PAYACK, JOSEPH F.; LARROW, JAY; TEFFERA, YOHANNES; HARMANGE, JEAN-CHRISTOPHE; DILMEGHANI SERAN, MINA; SUBRAMANIAN, RAJU; ZANON, ROGER AND MARTIN, MATTHEW W.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired